Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celularity Inc CELU

Financial Services Healthcare Biotechnology
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen... see more

Recent & Breaking News (NDAQ:CELU)

Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000®

GlobeNewswire June 8, 2022

Celularity Appoints Industry Leader Diane Parks to its Board of Directors

GlobeNewswire June 3, 2022

Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire May 18, 2022

Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 16, 2022

Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 31, 2022

Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference

GlobeNewswire March 15, 2022

Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

GlobeNewswire February 15, 2022

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

GlobeNewswire January 18, 2022

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

GlobeNewswire December 27, 2021

Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition

GlobeNewswire December 13, 2021

Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer

GlobeNewswire November 29, 2021

Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting

GlobeNewswire November 15, 2021

Celularity Reports Third Quarter 2021 Financial Results and Corporate Update

GlobeNewswire November 12, 2021

Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

GlobeNewswire September 20, 2021

Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

GlobeNewswire September 20, 2021

Celularity Appoints Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President

GlobeNewswire September 15, 2021

Celularity Reports Second Quarter 2021 Financial Results

GlobeNewswire August 16, 2021

GX Acquisition Corp. Announces Shareholder Approval of Extension Proposal

PR Newswire May 14, 2021

GX Acquisition Corp. Announces Additional Contributions to Trust Account

PR Newswire May 10, 2021

Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies

GlobeNewswire May 5, 2021